Higher biotech valuations in peer companies have provided comparative support to MYGN stock price, reducing downside risk while adding upside potential if market sentiment remains risk-on. Research and development expenses rose 10.4% year over year to $27.5 million. SG&A expenses dipped 0.3% to $69 million in the reported quarter. Boston Scientific Corporation (BSX) : Free Stock Analysis Report MYGN stock price charts show a bullish crossover in the 20-day moving average, aligning with positive sentiment in diagnostics and genetic research equities. Traders are setting alerts for volume spikes above $17.
